Indore, LIG Square - Oncology department

Madhumati Pahuja

CARE CHL Hospitals, Indore

Diffuse Large B-Cell Lymphoma

T-Cell Lymphoma

Prostatic Cancer

Follicular Lymphoma

Degarelix

AUR108

Aurigene Discovery Technologies

Ferring

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced lymphomas will be done to assess AUR108 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.

A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)

CARE CHL Hospitals | Indore, LIG Square - Oncology Department

Site insights

Contact this site

Active trials

A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)

Trial sponsors